ArticleJournal of orthopaedic case reports2026
Comparative Outcome Analysis of Leukocyte-Rich Platelet-rich Plasma, Leukocyte-Poor Platelet-rich Plasma, Injectable Platelet-rich Fibrin and Corticosteroid Injections in Periarthritis of the Shoulder: A Double-Blinded, Four-Arm Randomized Controlled Trial.
Article in Journal of orthopaedic case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Periarthritis of the shoulder (adhesive capsulitis) is a common, disabling condition. Autologous platelet concentrates have emerged as regenerative alternatives to corticosteroids. Still, the comparative efficacy of leukocyte-rich platelet-rich plasma (LR-PRP), leukocyte-poor platelet-rich plasma (LP-PRP), injectable platelet-rich fibrin (iPRF), and triamcinolone remains undefined. Objective: This study aimed to compare the efficacy, safety, and functional outcome of intra-articular LR-PRP, LP-PRP, iPRF, and triamcinolone in patients with periarthritis of the shoulder over 12 months. Materials and Methods: In this single-center, double-blinded, four-arm randomized controlled trial, 64 patients were allocated 1:1:1:1 (n = 16 per arm) to receive a single intra-articular injection of 5-6 mL LR-PRP, 5-6 mL LP-PRP, 5-6 mL iPRF, or 1 mL (40 mg) triamcinolone. The primary outcomes were the Visual Analog Scale (VAS) for pain and the disabilities of the Arm, Shoulder and Hand (DASH) score, assessed at baseline and at 1, 3, 6, and 12 months. Data were analyzed using repeated-measures analysis of variance in Statistical Package for the Social Sciences v26.0, with P < 0.05 considered significant. Results: All groups improved significantly from baseline (P < 0.001). At 1 month, the triamcinolone group showed the greatest improvement (VAS 3.1; DASH 30.2). From 6 months onward, the platelet-concentrate arms were superior; at 12 months, iPRF achieved the best outcomes (VAS 1.6 ± 0.6; DASH 15.0 ± 4.6), followed by LP-PRP (VAS 1.8; DASH 16.8) and LR-PRP (VAS 2.1; DASH 19.2), whereas the triamcinolone group regressed (VAS 4.2; DASH 37.4) (between-group P < 0.001 at 12 months). Adverse events were transient; post-injection swelling and pain were more frequent with LR-PRP. Conclusion: Corticosteroids offered the fastest early relief, but their effect was not durable. Platelet concentrates, particularly iPRF and LP-PRP, produced superior and sustained pain and functional benefit at 12 months with an excellent safety profile, supporting their use as durable regenerative options for periarthritis of the shoulder.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.